Free Trial

Erste Asset Management GmbH Buys New Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Apogee Therapeutics logo with Medical background
Remove Ads

Erste Asset Management GmbH purchased a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,000 shares of the company's stock, valued at approximately $1,099,000. Erste Asset Management GmbH owned about 0.05% of Apogee Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of APGE. Victory Capital Management Inc. lifted its holdings in Apogee Therapeutics by 121.6% during the 3rd quarter. Victory Capital Management Inc. now owns 346,358 shares of the company's stock worth $20,345,000 after buying an additional 190,092 shares during the last quarter. Natixis Advisors LLC purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at about $879,000. Jennison Associates LLC lifted its holdings in shares of Apogee Therapeutics by 2.1% in the 3rd quarter. Jennison Associates LLC now owns 312,611 shares of the company's stock valued at $18,363,000 after purchasing an additional 6,533 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at about $300,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Apogee Therapeutics by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company's stock valued at $16,472,000 after purchasing an additional 41,686 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total value of $732,750.00. Following the sale, the chief executive officer now owns 1,309,487 shares in the company, valued at $63,968,439.95. This represents a 1.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Carl Dambkowski sold 4,085 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the sale, the insider now owns 255,348 shares in the company, valued at approximately $11,986,035.12. This represents a 1.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,195 shares of company stock worth $2,026,392. Company insiders own 36.10% of the company's stock.

Remove Ads

Apogee Therapeutics Stock Up 4.2 %

APGE stock traded up $1.61 during trading on Friday, hitting $39.94. The company had a trading volume of 665,998 shares, compared to its average volume of 479,296. The firm has a 50-day moving average price of $38.21 and a 200-day moving average price of $46.59. Apogee Therapeutics, Inc. has a 1-year low of $29.10 and a 1-year high of $71.75. The firm has a market cap of $1.80 billion, a PE ratio of -16.50 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Wedbush reissued an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target on the stock. Finally, Citigroup began coverage on Apogee Therapeutics in a research report on Thursday. They issued a "buy" rating and a $95.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has an average rating of "Buy" and an average price target of $92.17.

Check Out Our Latest Stock Report on Apogee Therapeutics

Apogee Therapeutics Company Profile

(Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

See Also

Institutional Ownership by Quarter for Apogee Therapeutics (NASDAQ:APGE)

Should You Invest $1,000 in Apogee Therapeutics Right Now?

Before you consider Apogee Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.

While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads